Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design
Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating
Oncolytics got approval from the FDA on how to design their next big test for a cancer medicine. This is a good sign they're on the right track, but we won't know if the medicine actually works until they finish testing it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.